Parallel Advisors LLC Sells 6,797 Shares of Danaher Corporation $DHR

Parallel Advisors LLC reduced its stake in Danaher Corporation (NYSE:DHR) by 33.1% in the first quarter, HoldingsChannel reports. The institutional investor owned 13,731 shares of the conglomerate’s stock after selling 6,797 shares during the quarter. Parallel Advisors LLC’s holdings in Danaher were worth $2,603,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Danaher in the 4th quarter worth $2,177,106,000. Viking Global Investors LP lifted its position in shares of Danaher by 543.9% during the second quarter. Viking Global Investors LP now owns 2,907,515 shares of the conglomerate’s stock valued at $574,351,000 after purchasing an additional 2,455,994 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Danaher by 104.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,333,056 shares of the conglomerate’s stock worth $991,923,000 after purchasing an additional 2,216,789 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Danaher by 11.2% during the fourth quarter. Wellington Management Group LLP now owns 15,076,796 shares of the conglomerate’s stock worth $3,451,380,000 after purchasing an additional 1,517,904 shares during the last quarter. Finally, Capital International Investors grew its position in Danaher by 8.9% in the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock worth $4,177,386,000 after purchasing an additional 1,487,768 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on DHR. Barclays dropped their target price on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Rothschild & Co Redburn set a $205.00 target price on Danaher in a report on Friday, April 17th. Argus decreased their price target on Danaher from $265.00 to $230.00 and set a “buy” rating for the company in a research report on Friday, April 24th. TD Cowen dropped their price target on Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $240.00 price objective on shares of Danaher in a research report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $228.91.

Danaher Trading Up 0.2%

NYSE:DHR opened at $200.01 on Friday. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The firm’s 50 day moving average is $190.23 and its 200 day moving average is $194.24. The stock has a market capitalization of $140.61 billion, a PE ratio of 35.53, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the company earned $0.77 earnings per share. Danaher’s revenue was up 5.5% compared to the same quarter last year. Sell-side analysts expect that Danaher Corporation will post 8.53 earnings per share for the current year.

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.